Skip to main content
ICUI logo

ICUI · Icu Medical Inc

Track ICUI — free
$177.22 +0.31 (+0.18%)
Market Cap
$4.42B
Shares
25.01M
Volume · Nov 18 42.54K Avg daily vol (3M) 254.06K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$176.91 Open$179.18 Day$176.86–182.12 52W close$115.45–187.26 Avg vol 30d265K Short int1.7M · 6.7% of shares · 8.0d Short vol77% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 18, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 5
Earnings call
Q3 revenue grew 5% organically

ICU Medical reported Q3 revenue of $556 million, up 5% organically, with adjusted EBITDA of $114 million and adjusted EPS of $2.44; full-year guidance points toward the higher end of $415 to $435 million EBITDA and $8.60 to $9 EPS.

2 source passages
Revenue for Q3 was $556 million for total company growth of 5% on an organic basis, or 4% reported, as the reported results are no longer impacted by the mid-2025 creation of the Apsuka ICU Medical Joint Venture and the resulting deconsolidation of IV solutions from our income statement. Adjusted gross margins were strong at just over 42%, adjusted EBITDA improved to $114 million, and adjusted EPS was $2.44. And based on our performance in Q3 and our outlook for the remainder of the year, we now expect to finish the year towards the higher end of the previously provided guidance range of $415 to $435 million of EBITDA. And $8.60 to $9 for EPS. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Tariff refunds lift nine-month gross margin to 41.2%

ICU Medical, Inc. reported a 41.2% gross margin for the nine months ended September 30, 2026, up from 36.6%, with $29.2 million in tariff refunds boosting cost of goods sold.

Revenue $560.44M ▲ 4.4% Net income $26.85M Diluted EPS $1.07
Read from the MD&A section
3 source passages
ICU Medical, Inc. For the three and nine months ended September 30, 2026, gross margins were 41.9% and 41.2%, respectively, as compared to 37.4% and 36.6% for the same periods in the prior year. during the nine months ended September 30, 2026, $29.2 million of tariff refunds were recognized in cost of goods sold and $1.1 million of related interest income was recognized in interest expense, net. Open the document at this passage
Nov 5
Current report 8-K
Revenue and profit rise; fiscal-year guidance expected near high end

ICU Medical reported third-quarter GAAP revenue of $560.4 million and net income of $26.8 million, or $1.07 per diluted share. It reaffirmed fiscal year 2026 guidance and expects results near the high end.

Financial results
4 source passages
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026. Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0 million in the same period in the prior year. GAAP net income for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for the third quarter of 2025. The Company is reaffirming its full year 2026 guidance but expects to end the fiscal year towards the higher end of the guidance range. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.18B
Trailing 12 months
Net income (TTM)
$60.33M
Trailing 12 months
Revenue growth YoY
+4.4%
Year over year
Operating margin
5.1%
Trailing 12 months
P / E (TTM)
73.7
Trailing earnings · reciprocal yield 1.4%
FCF yield
4.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$850.07M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.9%
Year over year · more shares
Price change (1Y)
+31.5%
Trailing year
Short interest
6.7%
Latest settlement · 8.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. ICU Medical raised and narrowed its full-year 2026 guidance for adjusted EBITDA to $415-$435 million and adjusted EPS to $8.60-$9.00, with record Q2 results in Infusion Systems (13% reported, 12% organic) and Consumables (6% reported, 5% organic), while Vital Care declined 32% reported / 4% organic on IV Solutions deconsolidation.

Bullish
  • + Q2 Infusion Systems revenue grew 13% reported and 12% organic to a record in pumps.
  • + Full-year adjusted EBITDA guidance raised and narrowed to $415-$435 million from $400-$430 million.
  • + Full-year adjusted EPS guidance raised and narrowed to $8.60-$9.00 from $7.75-$8.45.
  • + Full-year adjusted gross margin guidance raised to ~41.5% on lower tariffs and accelerated synergy capture.
Bearish
  • − Vital Care revenue declined 32% reported / 4% organic in Q2 due to the May 2025 IV Solutions deconsolidation.
  • − Q2 restructuring, integration and strategic transaction expense rose to $21 million, including $10 million of non-cash asset write-offs tied to facility exits.
  • − GAAP diluted EPS fell to $0.76 from $1.43, and GAAP net income declined to $19.1 million from $35.3 million.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +18%
above
Price vs 50-day avg +8%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 86%
near high
Momentum
relative strength
Very Strong
1-month return +10%
trailing
6-month return +27%
trailing
YTD return +24%
this year
Relative strength +30%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $164 › 200d $150 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +50 funds added
Insider flow Distributing
Net -$315.9K over 90 days · 100% sells
Short interest Falling
6.69% of shares out · ▼ -2.4% MoM · 8.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
312 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Revenue growth −6%
Y/Y
Gross margin 37%
expanding
EPS growth +101%
Y/Y
Free cash flow $91.8M
Valuation P/E 73.7
in line
Buyback $100.0M
remaining
Balance sheet $976.7M
net debt
Quant / Vol
risk profile
Moderate
Volatility 36%
annualized · 1-yr
Max drawdown −27%
past year
ATR 3.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 5, 2026
GAAP net income · full year 2026 $73M – $83M
GAAP diluted earnings per share · full year 2026 Maintained $2.89 – $3.29
Aug 6, 2026 $2.89 – $3.29 changed to Nov 5, 2026 $2.89 – $3.29
prior FY $0.03 midpoint +10200.0% Y/Y
Adjusted EBITDA · full year 2026 Maintained $415M – $435M
Aug 6, 2026 $415M – $435M changed to Nov 5, 2026 $415M – $435M
Adjusted diluted earnings per share · full year 2026 Maintained $8.60 – $9.00
Aug 6, 2026 $8.60 – $9.00 changed to Nov 5, 2026 $8.60 – $9.00
Previous outlook earlier release · from the Earnings Call filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted gross margin · full year 2026 41.5%
Guided vs delivered · last 1 settled
GAAP diluted loss per share Fiscal Year 2023
guided $-3.00 – $-1.50
$-1.23 Beat +45.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+18% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
86% Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $164 › 200d $150 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +50 funds added
Insider flow Distributing
Net -$315.9K over 90 days · 100% sells
Short interest Falling
6.69% of shares out · ▼ -2.4% MoM · 8.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
312 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $115 Now $177 · 86% Range high $187
vs 200-day avg +18% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted (Non-GAAP) Total revenues non-GAAP 547.88M Three months ended June 30, 2026 —
Adjusted diluted earnings per share non-GAAP $2.37 second quarter of 2026 —
Adjusted EBITDA non-GAAP $110M second quarter of 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net income 19.09M
+15.75M Interest, net
+11.87M Stock compensation expense
+49.61M Depreciation and amortization expense
+21.3M Restructuring, strategic transaction and integration
+30K Settlements
+5.89M Quality system and product-related remediation
+0K Gain on sale of business
-1.12M Noncash release of loss on contract provision
-575K Gross profit on contract manufacturing
-18.89M Tariff refunds
+7.07M Provision for income taxes
= Adjusted EBITDA 110.03M
Free cash flow non-GAAP 89.27M Six months ended June 30, —
Net Debt non-GAAP 941.51M As of June 30, 2026 —
Net Leverage Ratio non-GAAP 2.28 As of June 30, 2026 —
non-GAAP organic revenue growth non-GAAP 6% second quarter of 2026 —
TTM Adjusted EBITDA non-GAAP 412.81M As of June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net income 30.09M
+72.69M Interest, net
+55M Stock compensation expense
+201.27M Depreciation and amortization expense
+71.69M Restructuring, strategic transaction and integration
+1.6M Settlements
+38.07M Quality system and product-related remediation
+887K Asset write-offs and similar charges
-2.97M Gain on sale of business
-4.39M Noncash release of loss on contract provision
-1.29M Gross profit on contract manufacturing
-18.89M Tariff refunds
-30.96M Provision for income taxes
= TTM Adjusted EBITDA 412.81M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ICUI
Icu Medical Inc
this stock
$4.42B +24.0% -6.3% 73.7 6.7%
ISRG
Intuitive Surgical Inc
$147.37B -24.0% +20.5% 51.5 2.0%
BDX
Becton Dickinson & Co
$58.68B — +8.2% 95.3 3.0%
MDLN
Medline Inc.
$49.56B -10.3% +11.5% — 2.9%
ALC
Alcon Inc
$35.60B -6.0% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
312
% held
101.1%
Net QoQ
-756.9K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
345
View
Short & Settlement
Short Interest Falling
Shares short
1.7M
Days to cover
8.0d
Change
-40.9K sh
View
Short Volume
Short vol %
77%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
12
Value
$1.9K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
43.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$315.9K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
May 6, 2025
View
Financials
Financials
Revenue (FY)
$2.2B
Net income (FY)
$732.0K
EPS diluted
$0.03
View
Buybacks
Authorized
$100.0M
Remaining
$100.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
17

ICU Medical reported third-quarter GAAP revenue of $560.4 million and net income of $26.8 million, or $1.07 per diluted share. It reaffirmed fiscal year 2026 guidance and expects results near the high end.

View
Proposed Sales
Value
$304.3K
Shares
1.7K
Filed
Nov 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
ICU Medical Announces Time of Thi…
Published
Oct 22, 2026
View

Performance

5D 20D 120D MTD YTD
ICUI -2.9% +9.8% +27.4% +8.0% +24.0%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -0.5% +14.6% +30.3% +11.1% +16.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$100.00M
Spent (derived)
$0
Remaining
$100.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 883984 CUSIP 44930G107 13F (30d) 333 filings 298 filers Visit website Investor relations